Evaluation of Antiphospholipid Antibody (APA) in COVID-19 Cases.

Recent works have been described regarding plethora of effects of COVID 19 on coagulation. Studies have even suggested that COVID -19 infection is associated with intra-alveolar fibrin deposition leading to respiratory failure. Hence, anticoagulant and fibrinolytic therapy are recommended to improve clinical outcomes . Few case series have implied that severely affected COVID -19 patients suffer from clinically significant thrombosis.Patients hospitalized for Covid-19 severe infection are more prone to excessive coagulation activation leading to thrombotic events. So, even though COVID 19 is a virus predominantly affecting respiratory system causing pneumonitis researchers have now highlighted thrombosis to be major pathology causing seriousness of patients.current scenario, there are only limited data on APLA in COVID 19 and also it is also not clear if they represent an epiphenomenon or are actually involved in any hemostatic abnormalities seen in COVID 19 disease. Current study will analyse whether antiphospholipid antibodies (IgG / IgM) will throw light on the contribution of thrombosis to seriousness of COVID-19 patients.